Germany's BioNTech signs deal with New Zealand for 1.5 million vaccine doses

Share

Initially, Rentschler will carry out current good manufacturing practice (cGMP) drug substance production of Covid-19 vaccine candidate, BNT162b2, developed by BioNTech in alliance with Pfizer.

BNT162b2 is an mRNA-based vaccine now in a Phase III trial at multiple sites globally. Two of these have entered phase -II trials after completing phase-I.

The latest payment will allow Mexico to acquire enough doses of a vaccine to immunize up to a fifth of the country's population of around 125 million people, the foreign ministry said. COVAX is being co-led by GAVI, the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI).

COVAX has been created to maximise the chances of successfully developing COVID-19 vaccines and manufacture them in the quantities needed to end this crisis.

According to the study, when respondents were asked if they were willing to accept less rigorous testing and faster approval of a coronavirus vaccine, almost half (43%) of parents surveyed globally said they were willing.

Taliban would welcome US troop withdrawal by Christmas
President Trump also highlighted massive investment in the USA military by his administration to restore its preparedness. Afghan officials have warned that swift USA withdrawal could further destabilize the country.

"Vaccine deals are underway and we are fast approaching our initial fundraising target to jumpstart support for lower-income countries", GAVI's chief executive, Dr Seth Berkley, told Reuters in a statement. Participants include about 76 wealthy, self-financing ones, but neither the United States nor Russian Federation. "Being part of COVAX actually provides significant buy-in to anything coming out of COVAX".

The announcement by the British embassy in Bangkok did not specify how many doses of the vaccine candidate, AZD1222, would be distributed in Thailand.

"The Cabinet note asked COVAX that we would like to have vaccines to vaccinate 33 per cent of the population [which is] about 462,000 persons". The goal is to have at least 60,000 patients to confirm the efficacy and safety of the vaccines in the first three months of the trial. At least four of China's Phase 3 vaccines are in the final stages of clinical trials and are approved for limited usage - two are being developed by state-backed China National Biotec Group, and two others by Sinovac Biotech and CanSino Biologics.

Ding said it remains unclear whether the US would join the initiative in the future. But by sharing supply equitably, countries and economies that are part of COVAX can distribute vaccines simultaneously to priority populations, including health workers, older people and those with underlying conditions. "Whether the US would join this, provide funding, or buy in significant output from this coalition is still a question".

Share